The Role of Upadacitinib on the Treatment of Ulcerative Colitis

Abstract

The JAK signaling pathway plays a major role in the immunopathology of autoimmune diseases, including inflammatory bowel disease. JAK enzymes provide novel targets for rapidly effective inflammatory bowel disease therapy, particularly in ulcerative colitis. Upadacitinib is a targeted JAK1 inhibitor. In multiple phase III clinical trials, upadacitinib has demonstrated significant improvement in clinical and endoscopic outcomes and quality of life for patients with moderate-to-severe ulcerative colitis. In this drug evaluation we describe the role of the JAK signaling pathway in ulcerative colitis, the mechanism of action of upadacitinib and the current clinical evidence for its use in ulcerative colitis; we also review its safety and tolerability, including for special populations.

Yerba Mate (Ilex paraguariensis) Reduces Colitis Severity by Promoting Anti-Inflammatory Macrophage Polarization

“…In fact, the regulation of the M1/M2 balance has recently been considered as a potential therapeutic strategy for IBD [ 21 , 22 ]. Currently, there are several treatments for ulcerative colitis such as pharmacological intervention, immunomodulators, gut microbiota modulation, and biological targeting [ 23 , 24 , 25 , 26 , 27 ]. However, these treatments are not effective in all patients; some are expensive and with diverse side effects [ 28 , 29 ].…”